Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination

George S Panagoulias1
John Doupis2,3
1 1st Department of Propaedeutic and Internal Medicine, Athens University Medical School, Laiko General Hospital, Athens, Greece; 2 Salamis Naval Hospital, Athens, Greece; 3 Diabetes Division, Iatriko Paleou Falirou Medical Center, Athens, Greece

Abstract: Fixed-dose combination (FDC) products represent a widely accepted approach to type 2 diabetes treatment, given that monotherapies sometimes fail to meet the treatment targets – obtaining a sustained reduction in micro- and macrovascular complications. Saxagliptin (SAXA)/metformin (MET) FDC tablets can be used either alone or in combination with glyburide, thiazolidinediones, or insulin. It has been proven that the SAXA/MET combination leads to a significant improvement in glycemic control compared to placebo in patients with type 2 diabetes that is inadequately controlled with MET alone. In addition, this FDC has been proven to be safe for people with diabetes mellitus and established cardiovascular disease, elderly patients, and patients with impaired renal function (≥30 mL/minute), with dosage modification. Patient compliance, adherence, and persistence to the therapeutic regimen has been shown to be very good, while the titration of each compound according to the patient’s profile is easy, given the availability of different formulations. The SAXA/MET FDC is a patient-friendly, dosage-flexible, and hypoglycemia-safe regimen with very few adverse events and a neutral or even favorable effect on body weight. It achieves significant glycosylated hemoglobin A1c reduction helping the patient to achieve his/her individual glycemic goals.

Keywords: DPP-4 inhibitors, saxagliptin, metformin, fixed-dose combination products, FDC products

Introduction to the challenges of treating type 2 diabetes

Type 2 diabetes has become a pandemic, holding the leading position of causes of death in USA.1 The American Diabetes Association guidelines suggest that good glucose control is the cornerstone for the management of short- and long-term diabetes complications.2 Furthermore, major studies have shown that tight glycemic control plays a significant role in the prevention of both micro- and macrovascular complications.3-5

Although diabetes awareness has significantly increased worldwide, almost half of the diabetic patients remain undiagnosed,4 and a large number of patients on antidiabetic treatment remain inadequately controlled.6 Poor compliance to the treatment and drug-related side effects6,8 are the main reasons why long-lasting, good glycemic control is not achieved.

Initial diabetes management includes lifestyle changes, with a focus on healthy diet, weight control, and increased physical activity. Metformin (MET) is widely considered to be the best first step in oral antidiabetic treatment, not only because of its efficacy in reducing the glycosylated hemoglobin A1c (HbA1c), but also due to its low
risk for hypoglycemia, its positive or neutral effect on body weight, its rare incidence of adverse effects, and its low cost.10

Early addition of a second oral hypoglycemic agent (OHA) or insulin has been suggested for cases in which MET monotherapy along with lifestyle modifications fail to achieve optimal HbA1c levels within 3–6 months.2,10,11 Adherence to medication in general depends on multiple factors, categorized by Blackburn et al into five groups: 1) characteristics of the patient; 2) characteristics of the treatment regimen; 3) features of the disease; 4) prescriber-level factors (including patient–physician relationship); and 5) the clinical setting.12 It has been proven that nonadherence to medication is very frequent in people with diabetes mellitus (DM),13 and leads to increased morbidity and mortality.14 Given that good patient compliance to hypoglycemic therapy is of crucial importance, tight glucose control must be achieved; the combination of two OHAs into a single tablet has been proven preferable to the administration of two separate agents, as this significantly simplifies the therapeutic regimen.15

The existing OHA single-tablet combinations include MET and sulfonylurea, MET and meglitinides, MET and thiazolidinediones (TZDs), sulfonylureas and TZD, and, more recently, MET and DPP-4 inhibitors (Table 1).16 DPP-4 inhibitors combined with MET have shown better outcomes in patients with poor glycemic control, compared to individual monotherapy.17,18

**Review of current and emerging therapies**

It has been more than 80 years since British clinician Harry Himsworth’s observations19 led to the conclusion that diabetes may not be the result only of the absolute lack of insulin, leading to the definition of type 2 diabetes. Only in 1958, though, did the first sulfonylurea became available on the market for the treatment of type 2 diabetes.19

Sulfonylureas are insulin secretagogues. They enhance insulin secretion by stimulating the pancreatic β-cells, consequently reducing the blood glucose through increased activity of the intracellular insulin receptors.20 Their main adverse events are hypoglycemia, mild weight gain, and possible early exhaustion of the β-cell.10

MET is considered to be the cornerstone of type 2 diabetes treatment. It has been used since 1959 in Europe, but only after 1995 in USA, due to the US Food and Drug Administration (FDA)’s concerns about possible toxicity.21 Its mechanisms of action include reduction of the hepatic glucose output and increase of insulin sensitivity. The most common adverse events of MET are gastrointestinal, sometimes leading to discontinuation of the treatment.5,22

Meglitinides are also insulin secretagogues, acting by inhibiting the adenosine triphosphate (ATP)-dependent potassium channels of the β-cells. They present a short half-time of action, thus have to be administered before each meal. Repaglinide and nateglinide are the two representatives of this category. Meglitinides are potent in reducing HbA1c, and present lower risk for hypoglycemia compared to sulfonylureas.22

Another class of OHAs are α-glucosidase inhibitors (acarbose and miglitol). These act by reducing the digestion rate of polysaccharides in the jejunum, presenting no effect on simple monosaccharides,22 and lower HbA1c up to 0.8%. Gastrointestinal side effects are the main reason for discontinuation of α-glucosidase inhibitor treatment.23

TZDs are peroxisome proliferator-activated receptor-γ activators. The only two chemical formulations in use, with various regional restrictions imposed worldwide, are pioglitazone and rosiglitazone. Their main mechanism of action in reducing hyperglycemia is through upregulation of insulin absorption from skeletal muscles and adipose tissue and reduction of gluconeogenesis.24 Apart from the fact that common side effects are weight gain and increased risk for bone fractures and peripheral edema, their main problem is that they are related to increased risk for myocardial infarction, while the latter is related to increased risk for macular edema and increased low-density lipoprotein levels.25-27

The only amylin mimic, pramlintide, an injectable synthetic analog of the β-cell hormone amylin that acts by delaying gastric emptying, is currently approved for use only in USA.10,28-30 Gastrointestinal side effects, the risk of severe hypoglycemic events, and the need to be coadministered with insulin,31 along with the lack of sufficient data concerning long-term safety, may be the reason for pramlintides limited use in USA and for its not being licensed in Europe.10

Sodium-glucose cotransporter 2 inhibitors are a novel class of OHA for the treatment of type 2 diabetes. They act by inhibiting the sodium-glucose transport protein subtype 2, which inhibits renal glucose reabsorption, consequently resulting in increased urinary glucose excretion. Currently, dapagliflozin is licensed only in Europe, while canagliflozin is licensed only in USA.32

Insulin has been the only hypoglycemic agent able to achieve eu glycemia both in fasting and postprandial states, followed by a consequent HbA1c reduction to optimal levels. The main problems from insulin treatments are weight gain,33 risk of hypoglycemia,33 and the need for extensive training of
Table 1 Completed clinical trials for saxagliptin supervised by the US National Institutes of Health

| Trial* | Type of study | Number of participants | Duration (weeks) | Compared** | HbA1c  
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01068743</td>
<td>BE</td>
<td>24</td>
<td>24</td>
<td>SAXA 2.5 mg/MET 850 mg FDC vs SAXA 2.5 mg + MET 850 mg</td>
<td>-2.53±0.070</td>
</tr>
<tr>
<td>NCT01192152</td>
<td>BE</td>
<td>30</td>
<td>24</td>
<td>SAXA 5 mg/MET 1,000 mg XR FDC vs SAXA 5 mg + MET 2×500 mg XR</td>
<td>-0.46±0.10</td>
</tr>
<tr>
<td>NCT01068717</td>
<td>BE</td>
<td>27</td>
<td>24</td>
<td>SAXA 2.5 mg/MET 500 mg FDC vs SAXA 2.5 mg + MET 500 mg</td>
<td>-0.94±0.075</td>
</tr>
<tr>
<td>NCT00899470</td>
<td>BE</td>
<td>24</td>
<td>24</td>
<td>SAXA 2.5 mg/MET 500 mg IR vs SAXA 5 mg vs MET 500–2,000 mg</td>
<td>-0.66±0.102</td>
</tr>
<tr>
<td>NCT00327015</td>
<td>EF/SAs</td>
<td>1,306</td>
<td>24</td>
<td>SAXA 5 mg + MET 500–2,000 mg vs SAXA 10 mg + MET 500–2,000 mg vs SAXA 5 mg vs MET 500–2,000 mg</td>
<td>-0.69±0.07</td>
</tr>
<tr>
<td>NCT00121641</td>
<td>EF/SAs</td>
<td>401</td>
<td>24</td>
<td>SAXA 2.5 mg, 5 mg, or 10 mg—placebo + MET 500–2,000 mg</td>
<td>-0.46±0.10</td>
</tr>
<tr>
<td>NCT00950599</td>
<td>EF</td>
<td>423</td>
<td>24</td>
<td>SAXA (2.5–5–10–20–40–100 mg) vs PL Multiple results</td>
<td>Multiple results</td>
</tr>
<tr>
<td>NCT01192139</td>
<td>BE</td>
<td>30</td>
<td>24</td>
<td>SAXA 5 mg/MET 500 mg XR FDC vs SAXA 5 mg + MET 500 mg VR</td>
<td>-0.94±0.075</td>
</tr>
<tr>
<td>NCT00295633</td>
<td>EF/SAs</td>
<td>565</td>
<td>24</td>
<td>SAXA 2.5 mg + TZDS vs SAXA 5 mg + TZDS vs PL + TZDS</td>
<td>-0.94±0.075</td>
</tr>
<tr>
<td>NCT00316082</td>
<td>EF/SAs</td>
<td>365</td>
<td>24</td>
<td>SAXA 2.5–5 mg vs PL</td>
<td>-0.66±0.102</td>
</tr>
<tr>
<td>NCT00121667</td>
<td>EF/SAs</td>
<td>743</td>
<td>24</td>
<td>SAXA 2.5–5–10 mg + MET (flexible dose) + pioglitazone 15–45 mg (as needed for rescue) vs PL/MET (flexible dose) + pioglitazone 15–45 mg (as needed for rescue)</td>
<td>-0.69±0.07</td>
</tr>
<tr>
<td>NCT00918138</td>
<td>EF/SAs</td>
<td>93</td>
<td>24</td>
<td>SAXA 5 mg/MET 1,500 mg FDC vs MET 2,000 mg</td>
<td>-19.0±5.69*</td>
</tr>
<tr>
<td>NCT00313313</td>
<td>EF/SAs</td>
<td>768</td>
<td>24</td>
<td>SAXA 2.5–5 mg + 7.5 mg glyburide vs PL + 7.5 mg glyburide</td>
<td>-0.64±0.059</td>
</tr>
<tr>
<td>NCT01128153</td>
<td>EF/SAs</td>
<td>257</td>
<td>24</td>
<td>SAXA 5 mg vs PL</td>
<td>-0.89 to -0.60</td>
</tr>
<tr>
<td>NCT00757588</td>
<td>EF/SAs</td>
<td>455</td>
<td>24</td>
<td>SAXA 5 mg + INS ± MET vs PL + INS ± MET</td>
<td>-0.73±0.054</td>
</tr>
<tr>
<td>NCT00575588</td>
<td>EF/SAs</td>
<td>858</td>
<td>104</td>
<td>SAXA 5 mg + MET vs 5–20 mg glipizide + MET</td>
<td>-0.74±0.038</td>
</tr>
<tr>
<td>NCT01006590</td>
<td>EF/TOs</td>
<td>286</td>
<td>24</td>
<td>SAXA 5 mg + MET 1,500 mg vs MET 1,500–2,500 mg</td>
<td>-0.47±0.06</td>
</tr>
<tr>
<td>NCT00689932</td>
<td>EF/SAs</td>
<td>568</td>
<td>24</td>
<td>SAXA 5 mg vs PL</td>
<td>-0.84±0.067</td>
</tr>
<tr>
<td>NCT00918879</td>
<td>EF/SAs</td>
<td>213</td>
<td>24</td>
<td>SAXA 5 mg vs PL</td>
<td>-0.51±0.098</td>
</tr>
<tr>
<td>NCT00683857</td>
<td>EF/SAs</td>
<td>93</td>
<td>24</td>
<td>SAXA 5 mg + MET XR vs PL + MET XR</td>
<td>-0.78±0.051</td>
</tr>
<tr>
<td>NCT00661362</td>
<td>EF/SAs</td>
<td>570</td>
<td>24</td>
<td>SAXA 5 mg + MET vs PL + MET</td>
<td>-0.78±0.051</td>
</tr>
<tr>
<td>NCT00614939</td>
<td>EF/SAs</td>
<td>170</td>
<td>24</td>
<td>SAXA 2.5 mg vs PL (renal impairment)</td>
<td>-1.35±0.174</td>
</tr>
</tbody>
</table>

Notes: Only trials with ≥24 weeks of medication are included. The gray-scaled rows refer to clinical trials with the SAXA/MET FDC. ClinicalTrials.gov identifier; *drugs compared; †adjusted mean change from baseline; Referring to maximum dose of the drug licensed for human use (%); ‡adjusted change from baseline. Referring to maximum dose of the drug licensed for human use (mg/dL); §change from baseline in 24-hour mean weighted glucose at week 4 (mg/dL).

Abbreviations: BE, bioequivalence; EF, efficacy; FDC, fixed-dose combination; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin A1c; IR, immediate release; MET, metformin; PL, placebo; SA, safety; SAXA, saxagliptin; TO, tolerability; TZDs, thiazolidinediones; XR, extended release; vs, versus; NCT, clinical trials identifier.

the patient in regards to the use of equipment. New insulin analogs, such as degludec and LY2605541 molecule, are under development.

Recently, bariatric surgery has entered the DM treatment field, arguing that it is a surgical disease. Meta-analyses have failed, however, to conclude whether remission of DM after metabolic surgery is sustained. The pharmaceutical industry is also targeting the development of new antidiabetic agents, such as insulin receptor signaling activators and insulin receptor tyrosine kinase activators, which are currently under investigation, with promising results so far.
Finally, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are two well-established new classes of antidiabetic agent based on the incretin effect.

The incretin effect
Clinical studies in the 1960s proved that oral glucose ingestion induces a greater increase in plasma insulin levels compared to intravenous administration of the same glucose amount. This was defined as the incretin effect, which is part of the intestinal hormone release, after oral glucose ingestion, resulting in increased insulin secretion.\(^{41,42}\)

The physiology of incretin effect is based mainly on the secretion of glucose-dependent insulinosuppressive polypeptide (GIP) from the intestinal K-cells and GLP-1 from the L-cells of the lower gut, after food intake. Both engage to structurally distinct G-protein-coupled receptors in \(\beta\)-cells but GIP only to \(\alpha\)-cells and GKP-1 only to \(\beta\)-cells of the pancreas. This leads to a rapid increase of the c-cyclic adenosine monophosphate and the intracellular calcium levels, followed by a consequent increase in insulin production.\(^{43,44}\)

GIP and GLP-1 are extensively and rapidly degraded by the enzyme DPP-4, which cleaves two terminal amino acids, converting the active polypeptides to their inactive form. Both the active and inactive forms of GIP and GLP-1 are cleared by the kidneys. Because of the rapid secretion and rapid inactivation of both GIP and GLP-1, their biologic actions are very short-lived and rapidly reversible.\(^{45}\)

GIP induces lipogenesis and stimulates glucagon secretion, while GLP-1 suppresses glucagon secretion during the postprandial period, slows gastric emptying, and increases satiety.\(^{46}\) GIP does not potentiate the antidiabetic effects of GLP-1 in patients with type 2 diabetes.\(^{47}\)

The antidiabetic effect of GLP-1 has opened new horizons for pharmaceuticals toward the development of new agents for treatment of type 2 diabetes based on the incretin effect. As a result, GLP-1 receptor agonists were produced in order to mimic and enhance the GLP-1 action; DPP-4 inhibitors were also produced in order to inhibit the action of GLP-1 inhibitors (DPP-4) and subsequently increase the levels of endogenously produced GLP-1.

GLP-1 receptor agonists
Currently, exenatide, liraglutide, and lixisenatide are commercially available. Albiglutide, a novel GLP-1 analog, is filed for approval in both USA and Europe, while dulaglutide is still in a Phase III study.\(^{47-49}\) GLP-1 analogs are a new, hypoglycemia-safe class of injectable antidiabetic agent, presenting significant glucose-lowering potency in patients with type 2 diabetes. When used as an adjunct to other treatments, they appear to lower A1c levels by 0.5% to 1%.\(^{50}\) Although some patients may experience gastrointestinal side effects (especially nausea), mainly at the beginning of therapy, patient treatment satisfaction is high, mainly due to convenience, flexibility, weight loss, lack of hypoglycemia, and glucose-lowering efficacy of the medication.\(^{31,52}\)

DPP-4 inhibitors
Also known as gliptins, DPP-4 inhibitors are another novel class of OHA, based on the incretin effect concept. The currently available gliptins worldwide are sitagliptin, vildagliptin, saxagliptin (SAXA), linagliptin, and alogliptin, while gemigliptin is available only in South Korea.\(^{53}\) Dutagliptin has completed Phase III clinical trials.\(^{53}\) According to the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes (EASD), DPP-4 inhibitors may be used as a second-line treatment for type 2 diabetes, after MET.\(^{10}\) The hypoglycemic action of DPP-4 inhibitors is mainly based on the increase of insulin secretion in a glucose-dependent way, as well as the suppression of glucagon secretion, as a result of the DPP-4 enzyme inhibition and the consequent increase of the circulating GLP-1. This results in an HbA1c reduction of up to 0.8%.\(^{54}\) Their main side effects include gastrointestinal discomfort as well as urticaria and angioedema;\(^{10}\) however, their low risk for hypoglycemia and good tolerance, together with their complementary mechanism of action in combination with MET, rank them high in the choice of therapeutic regimen.\(^{55}\)

SAXA
SAXA was the third DPP-4 inhibitor to be approved for human use by the FDA on July 31, 2009.\(^{56}\) Its chemical name, according to the International Union of Pure and Applied Chemistry (IUPAC) is (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0] hexane-3-carbonitrile hydrate, and its molecular formula and weight are C18H25N3O2·H2O and 333.43 (315.41 anhydrous), respectively.

SAXA appears as a water-soluble, white to off-white, crystalline powder, and its pKa value is 7.3. Its commercial name is Onglyza (Bristol-Myers Squibb, New York, NY, USA; AstraZeneca, London, UK) and it is on the market as an immediate-release, film-coated tablet containing 5 mg SAXA, supplied in alu/alu blister packaging.\(^{57}\) SAXA is FDA-approved to be used—along with diet and exercise—alone or in combination with other OHA (MET, sulfonylureas [glyburide], and TZDs).\(^{58}\) It is also licensed for triple oral therapy and in combination with
insulin therapy with or without MET. The efficacy and safety, as well as the bioequivalence studies used for granting the license in the US, are summarized in Table 2.

SAXA, when administered orally alone at the maximum dose of 5 mg, achieves a mean HbA1c reduction of 0.8% and a mean fasting plasma glucose reduction of 22 mg/dL. When coadministered with each therapeutic category of OHAs, it additionally reduces the mean HbA1c by 0.6%–0.7%. Furthermore, when it is coadministered with MET, at maximum tolerated dose and in MET-naïve patients, it achieves a mean HbA1c reduction of 2.5%, compared to placebo/MET combination.

The efficacy, safety, and the bioequivalence of SAXA/MET fixed-dose combination (FDC), in various dosage combinations, has been proven to be equal to administration of each compound separately, as shown in Table 1. Finally, according to the results of the SAVOR-TIMI 53 study of saxagliptin versus placebo, when added to standard of care in patients with T2DM at high CV risk, no increased risk of cardiovascular death, myocardial infarction, or ischemic stroke was demonstrated.

Materials and methods

A systematic search strategy was performed to identify randomized controlled trials in both MEDLINE (US National Library of Medicine, Bethesda, MD, USA) and ClinicalTrials.gov (US National Library of Medicine) until July 2013. The terms “saxagliptin,” “saxagliptin/metformin fixed dose combination,” “saxagliptin/metformin FDC,” “combination saxagliptin/metformin,” and “fixed dose of saxagliptin/metformin,” were incorporated into an electronic search strategy. Only papers in the English language were included in the search.

Studies with a duration of ≥24 weeks were included (Table 1). Trials with the SAXA/MET FDC are gray-scaled.

Methods of improving adherence to therapy: focus on combination formulations including SAXA/MET acceptability, adherence, and uptake

Nowadays, many new hypoglycemic agents are available for the treatment of type 2 diabetes, many of which are licensed, even for triple therapy. Thus, the quest for optimal glucose control often involves complex treatments, including multiple oral medications combined, sometimes with one or more insulin injections a day. This often affects adherence to the diabetes therapy, ultimately leading to inadequate glucose control.

Patient compliance, adherence, and persistence to the therapeutic regimen have been proven, since the Hippocratic era, to be crucial for the management of chronic diseases (Table 1). A systematic review regarding patients’ adherence to DM medication has shown that patients on either OHAs and insulin presented poor compliance to the treatment. Additionally, nonadherence to medication has been reported to be associated with higher hospitalization and mortality rates in patients with type 2 diabetes. Patients with poor adherence were younger, with less comorbidities as expected, presenting higher levels of HbA1c during follow-up.

In accordance with the above, the World Health Organization has reported that nonadherence to treatment is the leading cause of increased morbidity, mortality, and health care cost in preventable diseases. This assertion led to the formation of fixed-combined medication, called FDC products, in order to reduce the number of pills required per day and achieve the pursued targets, increasing adherence to the treatment. It has been shown that patients on monotherapy with inadequate glucose control are significantly improved when switching to FDCs compared to the add-on of a second OHA in a combination therapy. Additionally, conversion from monotherapy or polytherapy to an FDC has been proven to improve patient adherence rates by 23% and 16%, respectively.

A combined medication should ideally present complementary mechanisms of action and compatible pharmacokinetic characteristics. The combination of agents into a single tablet has been considered as an even better therapeutic option because it simplifies considerably the therapeutic regimen and maximizes patient compliance.

Given the above, the new SAXA/MET FDC represents a good choice for amplifying patients’ compliance and

Table 2 Existent dipeptidyl peptidase-4/metformin combinations worldwide (oral tablets)

<table>
<thead>
<tr>
<th>Combination</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin/metformin hydrochloride</td>
<td>50/500</td>
</tr>
<tr>
<td></td>
<td>50/850</td>
</tr>
<tr>
<td></td>
<td>50/1,000</td>
</tr>
<tr>
<td>Sitagliptin/metformin hydrochloride extended release</td>
<td>50/500</td>
</tr>
<tr>
<td></td>
<td>50/1,000</td>
</tr>
<tr>
<td></td>
<td>100/1,000</td>
</tr>
<tr>
<td>Vildagliptin/metformin hydrochloride</td>
<td>50/500</td>
</tr>
<tr>
<td></td>
<td>50/850</td>
</tr>
<tr>
<td></td>
<td>50/1,000</td>
</tr>
<tr>
<td>Saxagliptin/metformin hydrochloride extended release</td>
<td>5/500</td>
</tr>
<tr>
<td></td>
<td>5/1,000</td>
</tr>
<tr>
<td></td>
<td>2.5/1,000</td>
</tr>
<tr>
<td>Linagliptin/metformin hydrochloride</td>
<td>2.5/500</td>
</tr>
<tr>
<td></td>
<td>2.5/850</td>
</tr>
<tr>
<td></td>
<td>2.5/1,000</td>
</tr>
<tr>
<td>Alogliptin/metformin hydrochloride</td>
<td>12.5/500</td>
</tr>
<tr>
<td></td>
<td>12.5/1,000</td>
</tr>
</tbody>
</table>

Note: Data from www.drugs.com.
adherence to the therapeutic regimen. Given that the FDC is on the market in various milligram combinations (Table 1), the titration of each compound is easy and feasible, offering the clinician the flexibility to titrate up to the maximum tolerated dose for MET along with SAXA in a combined pill.

Even though coadministration of SAXA with submaximal doses of MET has not shown significant difference in HbA1c reduction compared to a maximal dose of MET alone,65 SAXA add-on to low MET dosages seems to be a good alternative treatment choice for patients with intolerance to high doses of MET.

**Efficacy, safety, and tolerability of SAXA/MET FDC**

Three recent studies have shown that SAXA/MET FDC was bioequivalent to separate SAXA and MET coadministration in both fasting and postprandial states, for both immediate and extended-release formulations. Moreover, tolerability, safety, and efficacy of the fixed formulations of SAXA/MET were comparable to those of each individual component when coadministered.66,67 Food consumption was found not to affect the pharmacokinetics of SAXA and MET when administered together as one formulation.67

A recent study has shown that adding SAXA to MET led to a statistically significant improvement in glycemic control compared to placebo in patients with type 2 diabetes inadequately controlled with MET alone.68 Since pharmacokinetics do not differ when SAXA and MET are given as a fixed combination, it is reasonable to expect the same results in the glycemic parameters.66

Additionally, it has been proven that DPP-4 inhibitors, and especially SAXA, when coadministered with MET, provide an additive or even synergistic effect on metabolic control in patients with type 2 diabetes.69 One study, comparing SAXA/glyburide combination with up-titrated glyburide, showed significantly better glucose control in the SAXA/glyburide group, as determined by HbA1c changes from baseline. This effect was sustained throughout the study.70 It has also been shown that, although sulfonylureas may be more effective in HbA1c reduction in maximal doses compared to gliptins, their potential adverse events are maximized.71

A crucial point in diabetes treatment with gliptins is cardiovascular safety.7 In a pooled analysis of Phase III clinical trials, SAXA has shown that is well tolerated in patients with established cardiovascular disease, as well as in patients with more than two risk factors for cardiovascular disease.72 Concerns regarding cardiovascular safety have been raised since 2008.73 SAXA is now being evaluated in the SAVOR-TIMI-53 [34] for cardiovascular safety as well as for its possible role in reducing the risk of cardiovascular events.74 Preliminary data have shown that SAXA have met the primary safety objective of noninferiority; but did not meet the primary efficacy objective of superiority for a composite end point of cardiovascular death, nonfatal myocardial infarction, or nonfatal ischemic stroke, when added to the patient’s current standard of care (with or without other antidiabetic therapies), compared to placebo.75 With regard to this, the SAXA/MET combination may be an alternative to the classical MET/sulfonylurea combination.74

SAXA/MET FDC has also been evaluated in older patients with type 2 diabetes, especially for safety and tolerance. The results of a post hoc analysis of pooled data from patients >65 years old from five Phase III clinical trials of 24-week duration have shown that SAXA/MET FDC was significantly effective in diabetes management and also very well tolerated. The risk of hypoglycemic events was low and adverse events were, in general, similar to those of younger patients.76

It is common knowledge that MET should be used with caution in patients with impaired renal function, as determined by estimated glomerular filtration rate (e-GFR), using any of the available formulas.77 In case e-GFR is less than 30 mL/minute, MET should be discontinued. Special attention should be given to patients with fluctuations in renal status.78 SAXA, on the other hand, requires no dose adjustment for patients with mild renal impairment (up to 50 mL/minute), whereas dose reduction by half is necessary for patients with e-GFR between 30–50 mL/minute. SAXA should be discontinued if e-GFR is less than 30 mL/minute;79 however, the lowest dose of SAXA (2.5 mg), administrated once daily, showed sustained efficacy and good tolerability for patients with type 2 diabetes and end-stage renal disease.80

In line with the above, SAXA/MET FDC 2.5/500 mg can be safely prescribed to subjects with type 2 diabetes and renal impairment with a e-GFR as low as 30 mL/minute.

**Patient-focused perspectives, such as quality of life, patient satisfaction/acceptability, and adherence**

When individualizing diabetes treatment, the goals and the personal preferences of the patient should be matched to the clinical profile of the hypoglycemic agents.81 Moreover, psychosocial barriers, fear of hypoglycemia, susceptibility to side effects, and drug-induced weight gain potential, should be taken into account for a tailor-made approach to the antidiabetic treatment.8,82
It has been proven that fear of adverse events has a great impact on patient adherence to medication, thus a hypoglycemia-safe class of OHAs with very few adverse events could possibly improve compliance. The SAXA/MET FDC represents a hypoglycemia-safe choice with excellent tolerability and very few adverse events that also provides a significant contribution to HbA1c reduction in patients with type 2 diabetes. Adverse events of SAXA/MET FDC in both older (>65 years) and younger subjects have been proven to be very low in a post hoc analysis.

Another significant determinant of treatment compliance has been proven to be the age of the patient. Studies have shown that younger patients tend to present poor glycemic control and a large number of prescribed OHAs. In addition, younger patients with DM present lower adherence to therapy compared to older ones. These differences between younger and older patients could possibly be attributed to unscheduled meals due to the way of living and working, and discrepancies in intra-daily nutrient intake. The frequency and timing of the dosing of the antidiabetic agents seems to be very important in these cases. FDCs provide flexible regimens with reduced number of pills and easy titration of the medications. SAXA/MET fixed combination may represent an ideal choice for the management of diabetes in this age group.

The fear of weight gain is another factor that could significantly influence adherence to diabetes treatment as well. The effect of DPP-4 inhibitors on body weight has been proven to be neutral or mildly favorable. It has also been shown that their mild weight-lowering effect is maximized when they are coadministered with MET. Given that weight control is very important for patients with type 2 diabetes, preference should be given to hypoglycemia-safe and weight-neutral agents, targeting also maximum compliance to the treatment. The SAXA/MET fixed combination seems to address this crucial point of adherence. In younger ages, weight control is even more significant, since obesity bears a negative psychosocial burden as well.

It is noteworthy that the main disadvantage of DPP-4 inhibitors is their high cost. It has been proven that better adherence to treatment of chronic diseases is associated with significant cost reduction for the health care system, mainly due to the reduction in long-term complications of the diseases. Unfortunately, there is a lack of data regarding the possible association between the use of DPP-4 inhibitors for type 2 diabetes and the direct health care cost. To estimate the possible cost effectiveness of DPP-4 inhibitors, models based on cost and quality-adjusted life years (QALYs) estimation have been used. In such models, the use of the SAXA/MET combination has been proven to be cost-effective, from the perspective of the social security system in Argentina. A simulation model based on the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (68) has been used to calculate the disease progression and to estimate the economic and health treatment consequences, derived from micro- and macrovascular complications in people with type 2 diabetes, during a 20-year follow up. In this model, a SAXA/MET-treated group was compared to a SU/MET-treated group. The former presented a lower number of both fatal and nonfatal macrovascular events compared to the latter. Although the total cost to treat, of the SAXA/MET-treated group was 15% higher than that of the SU/MET group, the treatment with SAXA/MET resulted in a higher number of QALYs and life-years gained, while the incremental cost per QALY and life-year gained was US$7,374 and US$20,490, respectively.

In another discrete event-simulation model, the add-on of SAXA to MET was compared to the add-on of pioglitazone or rosiglitazone to MET, in a 3-year follow-up. The estimated cost-utility ratio (cost per QALY) and budget impact model was built to simulate the economic impact of SAXA. From the perspective of private paying source, i.e., the payment of the medication directly by the patient, the projection showed that the SAXA/MET combination presented lower costs compared to the TZD/MET combination in patients with type 2 diabetes who had not reached the HbA1c goal with MET monotherapy.

Conclusion
Achieving good outcomes in diabetes has been proven to be associated with the treatment selection as well as with the adherence of the patient to the therapy. Thus, full individualization of the diabetes treatment should be focused on meeting the needs of the patient – fitting in with his/her everyday life schedule and addressing his/her personal psychosocial aspects. From the patient’s point of view, it remains unclear whether better quality of life is achieved just by alleviation of the symptoms of the disease.

It seems that the SAXA/MET FDC is a patient-friendly, dosage-flexible, and hypoglycemia-safe regimen. Combining very few adverse events with a neutral or even favorable effect on body weight, it is also potent enough to achieve significant HbA1c reduction and help the patient to achieve his/her individual glycemic goals.

Disclosure
The authors report no conflicts of interest in this work.
References


